FIGURE 3.

Inhibition of NAMPT by FK866 resulted in alteration of pentose phosphate pathway intermediate levels in cancer cells. A2780 (A) and HCT116 (B) cells were grown and treated in triplicate with FK866 at various concentrations and ± nicotinic acid (10 μm) as described (“Experimental Procedures”). After the treatment, cells were collected and processed for the analysis of 6-phosphogluconate (Gn6P), pentose phosphates (R5P), and sedoheptulose 7-phosphate (S7P) levels by LC-MS (“Experimental Procedures”). Error bars represent S.D. *, p ≤ 0.001 versus control.